Dr. Reddy’s entered into a license agreement for the production of ramdevpir

Dr. Reddy’s entered into with Gilead license agreement in relation to the registration, manufacture, and sale of a medicinal product of ramdevpir, which is currently being considered as a potential means of therapy COVID-19. It is reported Bloomberg.

The agreement of the parties extends to 127 countries. After the transfer of the production of Dr. Reddy’s will be responsible for the increase in the production of the drug and ensuring the registration process in each country.

Currently ramdevpir approved in the USA for the treatment of COVID-19 in an emergency situation. The drug also is approved for this indication in the EU.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]